semaglutide california banned Medi-Cal coverage of weight loss drugs on chopping block under CA proposal The FDA's Decision to Ban

Various components of MetS are investigated, including visceral obesity, dyslipidemia, elevated blood pressure, impaired fasting glucose, and insulin resistance

Watch What are Ozempic babies and why are women reporting being pregnant while on weight-loss drugs

Semaglutide data were analyzed to assess effects of treatment as a function of CV risk predicted using the CV risk prediction model

Is Motility Something You Need to Stay on Long-Term

Joint discomfort during GLP-1 therapy can stem from rapid weight loss, medication response, or individual metabolic factors

Thriving on GLP-1 for Metabolic & Weight Management is a three-week workshop that explains the science of obesity, weight regulation, how GLP-1 medications work, and their benefits